Clinical Research Directory
Browse clinical research sites, groups, and studies.
Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
Sponsor: Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Summary
The objective of this observational study is to investigate the long-term effects of Hetrombopag in promoting platelet engraftment during haploidentical hematopoietic stem cell transplantation (HSCT) in children with thalassemia, with a specific focus on a 28-day time window post-transplantation. The core question to be addressed is: Is Hetrombopag safe and effective for platelet engraftment in children with thalassemia undergoing haploidentical HSCT within a 28-day post-transplant period? Subjects who received Hetrombopag as part of routine care for haploidentical HSCT in children with thalassemia will be required to complete a 28-day online survey on platelet engraftment outcomes.
Official title: An Observational Study on the Promotion of Platelet Recovery by Hetrombopag During Haploidentical Hematopoietic Stem Cell Transplantation
Key Details
Gender
All
Age Range
2 Years - 17 Years
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2024-09-01
Completion Date
2026-04-30
Last Updated
2025-06-04
Healthy Volunteers
No
Conditions
Interventions
Hetrombopag
In allogeneic hematopoietic stem cell transplantation, hetrombopag is initiated at 3 µg/kg subcutaneously on day +6 post-transplant. The dose is increased by 2 µg/kg weekly up to a maximum of 10 µg/kg. Treatment is discontinued when platelet counts rise to 100×10⁹/L. If platelet counts remain ≤20×10⁹/L on day +20, hetrombopag is combined with eltrombopag 25 mg orally once daily. Fresh apheresis platelet suspensions (1 therapeutic dose, containing \>2.5×10¹¹ platelets) are administered when platelet counts are ≤20×10⁹/L or when counts are between 21-50×10⁹/L with active bleeding. If engraftment has not occurred by day +28 post-transplant, re-transplantation is required, and hetrombopag is considered ineffective.
Locations (1)
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Haikou, Hainan, China